FGFR2 and cancer: Besides the high potency of erdafitinib against malignancies harboring FGFR2 mutations and other rearrangements, several recent studies have demonstrated its “off-target” effect to sensitize cancer cells to certain chemotherapies due to its ability to interact with ABCB1 and impair its function.